Abstract
Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are associated with a variety of extra-intestinal manifestations (EIMs). About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract. The EIMs associated with IBD have a negative impact on patients with UC and CD, and the resolution of most of them parallels that of the active IBD in terms of timing and required therapy; however, the clinical course of EIMs such as axial arthritis, pyoderma gangrenosum, uveitis, and primary sclerosing cholangitis is independent of IBD activity. The peripheral and axial arthritis associated with IBD have traditionally been treated with simple analgesics, non-steroidal anti-inflammatory drugs, steroids, sulfasalazine, methotrexate, local steroid injections and physiotherapy, but the introduction of biological response modifiers such as tumor necrosis factor-α blockers, has led to further improvements.
| Original language | English |
|---|---|
| Pages (from-to) | 2469-2471 |
| Number of pages | 3 |
| Journal | World Journal of Gastroenterology |
| Volume | 15 |
| Issue number | 20 |
| DOIs | |
| Publication status | Published - May 28 2009 |
Fingerprint
Keywords
- Anti-tumor necrosis factor antagonists
- Arthropathies
- Inflammatory bowel disease
- Treatment
ASJC Scopus subject areas
- Gastroenterology
Cite this
Combined therapeutic approach : Inflammatory bowel diseases and peripheral or axial arthritis. / Atzeni, Fabiola; Ardizzone, Sandro; Bertani, Luca; Antivalle, Marco; Batticciotto, Alberto; Sarzi-Puttini, Piercarlo.
In: World Journal of Gastroenterology, Vol. 15, No. 20, 28.05.2009, p. 2469-2471.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Combined therapeutic approach
T2 - Inflammatory bowel diseases and peripheral or axial arthritis
AU - Atzeni, Fabiola
AU - Ardizzone, Sandro
AU - Bertani, Luca
AU - Antivalle, Marco
AU - Batticciotto, Alberto
AU - Sarzi-Puttini, Piercarlo
PY - 2009/5/28
Y1 - 2009/5/28
N2 - Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are associated with a variety of extra-intestinal manifestations (EIMs). About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract. The EIMs associated with IBD have a negative impact on patients with UC and CD, and the resolution of most of them parallels that of the active IBD in terms of timing and required therapy; however, the clinical course of EIMs such as axial arthritis, pyoderma gangrenosum, uveitis, and primary sclerosing cholangitis is independent of IBD activity. The peripheral and axial arthritis associated with IBD have traditionally been treated with simple analgesics, non-steroidal anti-inflammatory drugs, steroids, sulfasalazine, methotrexate, local steroid injections and physiotherapy, but the introduction of biological response modifiers such as tumor necrosis factor-α blockers, has led to further improvements.
AB - Inflammatory bowel diseases (IBDs), particularly Crohn's disease (CD) and ulcerative colitis (UC), are associated with a variety of extra-intestinal manifestations (EIMs). About 36% of IBD patients have at least one EIM, which most frequently affect the joints, skin, eyes and the biliary tract. The EIMs associated with IBD have a negative impact on patients with UC and CD, and the resolution of most of them parallels that of the active IBD in terms of timing and required therapy; however, the clinical course of EIMs such as axial arthritis, pyoderma gangrenosum, uveitis, and primary sclerosing cholangitis is independent of IBD activity. The peripheral and axial arthritis associated with IBD have traditionally been treated with simple analgesics, non-steroidal anti-inflammatory drugs, steroids, sulfasalazine, methotrexate, local steroid injections and physiotherapy, but the introduction of biological response modifiers such as tumor necrosis factor-α blockers, has led to further improvements.
KW - Anti-tumor necrosis factor antagonists
KW - Arthropathies
KW - Inflammatory bowel disease
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=67650133676&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650133676&partnerID=8YFLogxK
U2 - 10.3748/wjg.15.2469
DO - 10.3748/wjg.15.2469
M3 - Article
C2 - 19468996
AN - SCOPUS:67650133676
VL - 15
SP - 2469
EP - 2471
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
SN - 1007-9327
IS - 20
ER -